logo
Share SHARE
FONT-SIZE Plus   Neg

Derma Sciences Buys Global Long-Term Exclusive Rights To NIMBUS Technology

Derma Sciences Inc. (DSCI) and Quick-Med Technologies Inc. reached an agreement, whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology, which is available in BIOGUARD dressings.

As per the deal, Derma Sciences would make a $1.3 million upfront payment to Quick-Med Technologies and future milestone payments based on sales of products incorporating the licensed technology. Further, the royalty paid by Derma Sciences to Quick-Med Technologies on such products would be lowered from 20% currently, to a sliding scale starting at 8.5% and declining as sales milestones are achieved.

Sales by Derma Sciences of products covered under this deal were some $1.5 million in 2011, and may grow between 30% and 40% annually, in line with view for the company's advanced wound care product portfolio.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French car maker Renault SA reported Friday higher profit in its fiscal 2015, with strong growth in automotive profit and revenues. The company announced higher dividend. Looking ahead, for fiscal 2016, Renault expects to increase group revenues at constant exchange rates and improve group operating margin. Shares of Rolls-Royce Holdings Plc were gaining around 13 percent in the morning trading in London after the engine maker reported more-than doubled profit in its fiscal year 2015, with lower one-time items. Underlying earnings were hurt by weakness in Marine markets. Further, the company halved its dividends, and still expects lower revenues next year. German steel giant ThyssenKrupp AG reported a loss in its first quarter, compared to last year's profit as sales and orders were hurt by sharp deterioration in materials businesses. The company said its overall performance in the first quarter was within its full-year forecast corridor. Looking ahead, the company continues to expect higher net income and flat sales for fiscal 2016.
comments powered by Disqus
RELATED NEWS
Trade DSCI now with 
Follow RTT